Hepatitis C News and Research

Latest Hepatitis C News and Research

First Edition: April 15, 2014

Today's headlines include reports about the Congressional Budget Office's latest estimate of the costs for expanding health insurance.

15 Apr 2014

New data focuses on different approaches to improve diagnosis and treatment of HCC

Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC).

15 Apr 2014

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle.

15 Apr 2014

New drug combination proves effective in treating patients with HCV genotype 1

Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials led by Beth Israel Deaconess Medical Center show promise for a new option that could help lead to both an increase in patients cured with a much more simple and tolerable all oral therapy.

15 Apr 2014

High cost of potent hepatitis drug presents challenges across the U.S.

Sovaldi, the hepatitis C treatment drug, is considered a breakthrough for patients with the disease. However, since, it won federal approval in December, lawmakers, insurers and patient advocates have begun an all-out revolt over it's high price point of $1,000 a daily pill or $84,000 over 12 weeks of treatment.

15 Apr 2014

New data shows that gut microbiota has potential role in development of ALD

Exciting new data presented today at the International Liver Congress- 2014 shows that the gut microbiota has a potential role in the development of alcoholic liver disease (ALD).

15 Apr 2014

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute.

15 Apr 2014

New paper calls for increase in geographically targeted prevention, treatment for HIV-infected people

In U.S. cities, it's not just what you do, but also your address that can determine whether you will get HIV and whether you will survive. A new paper in the American Journal of Public Health illustrates the effects of that geographic disparity - which tracks closely with race and poverty - and calls for an increase in geographically targeted prevention and treatment efforts.

11 Apr 2014

New research provides new hope for liver transplant patients with recurring hepatitis C

New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).

11 Apr 2014

EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

New ways to differentiate between chronic and self-clearing infections may help towards effective patient management and reduce drug costs. But there are major challenges in implementation.

11 Apr 2014

Viral hepatitis linked to more deaths than HIV across EU countries

Mortality from viral hepatitis is significantly higher than from HIV/AIDS across EU countries, according to results from The Global Burden of Disease Study 2010 (GBD 2010) which was announced for the first time today at the International Liver CongressTM 2014.

11 Apr 2014

Researcher develops novel IBT to help opioid-dependent Vermonters

Opioid dependence - addiction to heroin and prescription painkillers - has reached epidemic levels across the country, with treatment waitlists also at an all-time high.

11 Apr 2014

Housing projects in developing world expose low-income workers to natural disasters, disease

Satellite city projects across the developing world are putting an increasing number of poor people at risk to natural hazards and climate change, according to a new study from the University of Colorado Denver.

11 Apr 2014

Clinical Research Forum announces winners of third annual Top 10 Clinical Research Achievement Awards

The Clinical Research Forum has announced the winners of its third annual Top 10 Clinical Research Achievement Awards. The winning projects represent the outstanding examples of research projects that benefit the health and well-being of the general public.

11 Apr 2014

Assembly Pharmaceuticals, BioCrossroads develop novel drugs that have potential to treat chronic HBV infection

Assembly Pharmaceuticals and BioCrossroads today announced that the BioCrossroads Indiana Seed Fund II has made an investment in Assembly Pharmaceuticals. Assembly is developing novel drugs for the treatment and potential cure of chronic hepatitis B virus (HBV) infection.

10 Apr 2014

Johns Hopkins student receives 2014 Excellence in Public Health Award

Ramy El-Diwany, a fifth-year M.D./Ph.D. student at the Johns Hopkins University School of Medicine, has won a 2014 Excellence in Public Health Award from the U.S. Public Health Service (USPHS) Physician Professional Advisory Committee for his contributions to community health services.

10 Apr 2014

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection.

10 Apr 2014

Small financial incentives can improve people’s completion of HBV vaccination, study finds

Small financial incentives, totalling as little as £30, can dramatically increase the likelihood of people who inject drugs completing a course of hepatitis B virus (HBV) vaccination, according to new research published in The Lancet.

10 Apr 2014

Portrait of newly insured takes shape

Early enrollees in the health law's marketplaces were more likely to use expensive specialty drugs and less likely to use contraceptives, according to an analysis of two months of drug claims data by Express Scripts. A Rand analysis, meanwhile, argues that most of the newly insured signed up with an employer rather than buying it through the marketplaces.

10 Apr 2014

First Edition: April 9, 2014

Today's headlines include coverage of the release of Medicare billing and utilization data, as well as early insights into who enrolled in health coverage as a result of the health law.

9 Apr 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

First Edition: April 15, 2014

New data focuses on different approaches to improve diagnosis and treatment of HCC

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

New drug combination proves effective in treating patients with HCV genotype 1

High cost of potent hepatitis drug presents challenges across the U.S.

New data shows that gut microbiota has potential role in development of ALD

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

New paper calls for increase in geographically targeted prevention, treatment for HIV-infected people

New research provides new hope for liver transplant patients with recurring hepatitis C

EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

Viral hepatitis linked to more deaths than HIV across EU countries

Researcher develops novel IBT to help opioid-dependent Vermonters

Housing projects in developing world expose low-income workers to natural disasters, disease

Clinical Research Forum announces winners of third annual Top 10 Clinical Research Achievement Awards

Assembly Pharmaceuticals, BioCrossroads develop novel drugs that have potential to treat chronic HBV infection

Johns Hopkins student receives 2014 Excellence in Public Health Award

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Small financial incentives can improve people’s completion of HBV vaccination, study finds

Portrait of newly insured takes shape

First Edition: April 9, 2014

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in